Skip to main content

KPTI

Stock
Health Care
Biotechnology

Performance overview

KPTI Price
Price Chart

Forward-looking statistics

Beta
2.09
Risk
91.30%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Company info

SectorHealth Care
IndustryBiotechnology
Employees415
Market cap$119.7M

Fundamentals

Enterprise value$227.5M
Revenue$142.1M
Revenue per employee—
Profit margin-43.99%
Debt to equity-1.26

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$11.87
Dividend per share—
Revenue per share$17.09
Avg trading volume (30 day)$283K
Avg trading volume (10 day)$203K
Put-call ratio—

Macro factor sensitivity

Growth-1.1
Credit+2.1
Liquidity+1.1
Inflation-6.0
Commodities-0.8
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-6.18
Price to sales0.27
P/E Ratio-6.18
Enterprise Value to Revenue1.60
Price to book-0.18

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research (May 26, 2025)
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.

Benzinga (May 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free